Table 1.
Demographics and baseline characteristics.
| Characteristics (N = 44). | n | % | Characteristics (N = 44) | n | % |
|---|---|---|---|---|---|
| Center | pT stage (MD=9) | ||||
| Lille | 22 | 50.0% | pT1a | 4 | 11.4% |
| Nancy | 15 | 34.1% | pT1c | 8 | 22.9% |
| Caen | 7 | 15.9% | pT2 | 16 | 45.7% |
| pT3 | 7 | 20.0% | |||
| Age at diagnosis (MD=1) | |||||
| Median (range) | 51 | (31.0;79.0) | pN stage (MD=8) | ||
| Average/standard deviation | 53.4 | 12 | pN0 | 13 | 36.1% |
| pN1 | 16 | 44.4% | |||
| Histological type (MD=1) | pN2a | 4 | 11.1% | ||
| NST | 35 | 81.4% | pN3 | 3 | 8.3% |
| ILC | 7 | 16.3% | |||
| Other | 1 | 2.3% | HR Status (MD=5) | ||
| ER+ PR+ | 23 | 59.0% | |||
| cT stage (MD=13) | ER+ PR- | 10 | 25.6% | ||
| cT1a | 1 | 3.2% | ER- PR- | 6 | 15.4% |
| cT1c | 5 | 16.1% | |||
| cT2 | 12 | 38.7% | HER2 status | ||
| cT3 | 12 | 38.7% | Negative | 32 | 82.1% |
| cT4 | 1 | 3.2% | Positive | 7 | 17.9% |
| cN stage (MD=14) | Grade (MD=7) | ||||
| cN0 | 15 | 50.0% | 1 | 3 | 8.1% |
| cN1 | 12 | 40.0% | 2 | 24 | 64.9% |
| cN3 | 2 | 6.7% | 3 | 10 | 27.0% |
| cNx | 1 | 3.3% | |||
| Ki-67% (MD=21) | |||||
| cM stage (MD=7) | Median - (range) | 20 | (3.0;90.0) | ||
| M0 | 16 | 43.2% | Average/standard deviation | 22.8 | 18.3 |
| M1 | 21 | 56.8% | |||
| Vascular emboli (MD=18) | 11 | 42.30% | |||
| Systemic treatment (MD=8) | 19 | 52,8% | |||
| Chemotherapy | 6 | 16,7% | |||
| Hormonotherapy. | 13 | 36,1% |
With MD, missing data; stage c, clinical stage; stage p, pathological stage; T, tumor; N, lymph node; M, metastasis; NST, no special type; ILC, invasive lobular carcinoma [sic]; HR, hormone receptors; ER, estrogen receptors; PR, progesterone receptors, and HER2, human epidermal growth factor receptor type 2.